Branch Retinal Vein Occlusion Clinical Trial
— BlossomOfficial title:
A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]
Verified date | February 2017 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
Status | Completed |
Enrollment | 283 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: • Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye. Exclusion Criteria: - Pregnant or nursing women or women of child bearing potential without using an effective contraception - Stroke or myocard infarction within 3 months prior to study - History of malignancy within the past 5 years - Uncontrolled hypertension - Active infection or inflammation in any eye - monocular patients - use of corticosteroids for at least 30 days in the last 6 months - treatment with anti-angiogenic drugs in any eye within last 3 months - laser photocoagulation within the last few months - Other protocol defined inclusion/exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
China | Novartis Investigative Site | Beijing | Beijing |
China | Novartis Investigative Site | Beijing | Beijing |
China | Novartis Investigative Site | Beijing | |
China | Novartis Investigative Site | Beijing | |
China | Novartis Investigative Site | Beijing | |
China | Novartis Investigative Site | Changsha | Hunan |
China | Novartis Investigative Site | Chengdu | Sichuan |
China | Novartis Investigative Site | Chongqing | Chongqing |
China | Novartis Investigative Site | Chongqing | |
China | Novartis Investigative Site | Guangzhou | Guangdong |
China | Novartis Investigative Site | Harbin | Heilongjiang |
China | Novartis Investigative Site | Nanchang | Jiangxi |
China | Novartis Investigative Site | Nanjing | Jiangsu |
China | Novartis Investigative Site | Nanjing | Jiangsu |
China | Novartis Investigative Site | Nantong | Jiangsu |
China | Novartis Investigative Site | Qingdao | Shandong |
China | Novartis Investigative Site | Shanghai | |
China | Novartis Investigative Site | Shanghai | |
China | Novartis Investigative Site | Shantou | Guangdong |
China | Novartis Investigative Site | Tianjin | Tianjin |
China | Novartis Investigative Site | Tianjin | Tianjin |
China | Novartis Investigative Site | Wenzhou | Zhejiang |
China | Novartis Investigative Site | Wuhan | Hubei |
Hong Kong | Novartis Investigative Site | Hongkong | |
Indonesia | Novartis Investigative Site | Bandung | Jawa Barat |
Indonesia | Novartis Investigative Site | Jakarta | |
Philippines | Novartis Investigative Site | Manila | Metro Manila |
Philippines | Novartis Investigative Site | San Juan City | |
Taiwan | Novartis Investigative Site | Kaohsiung | |
Taiwan | Novartis Investigative Site | Lin-Kou | |
Taiwan | Novartis Investigative Site | Taipei | |
Vietnam | Novartis Investigative Site | Hanoi | |
Vietnam | Novartis Investigative Site | Ho Chi Minh City |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
China, Hong Kong, Indonesia, Philippines, Taiwan, Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of Best Corrected Visual Acuity (BCVA) in patients treated with ranibizumab 0.5 mg prn or sham injection. | Assessment of efficacy of treatment with 0.5 mg ranibizumab prn compared to treatment with sham injection over 6 months. The change of BCVA will be assessed by the change from baseline BCVA to the average level of BCVA over all monthly assessments from month 1 to month 6 | Baseline, 6 months | |
Secondary | Average change of Best Corrected Visual Acuity (BCVA) in patients treated with ranibizumab 0.5 mg prn | The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet. | Baseline, 12 months | |
Secondary | Best Corrected Visual Acuity (BCVA) change over time | The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet. | 12 months | |
Secondary | Change in Central-Sub-Field- Thickness (CSFT) | Retinal thickness was assessed by Optical Coherence Tomography (OCT) and was analyzed by the central reading center. | Baseline, 12 months | |
Secondary | Categorical BCVA improvement over time | BCVA improvement of >= 5, >= 10, >=15 and >= 30 letters from baseline over time (month 1 through month 12) | 12 months | |
Secondary | Percentage of patients with Best Corrected Visual Acuity (BCVA) loss < 15 letter | BCVA loss < 15 letters from baseline over time (month 1 through month 12) | 12 months | |
Secondary | Number of patients with active leakage | Area of leakage was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. | month 3, 6 and 12 | |
Secondary | The change in patient reported outcomes in NEI-VFQ-25 score (composite score and subscales) at month 3, 6 and 12 compared to baseline | Effect of treatment on absolute composite- and subscale scores and changes from baseline over time of vision related quality of life assessed by the patient on the Vision Functioning Questionaire (VFQ-25) | Baseline, months 3, 6 and 12 | |
Secondary | Number of participants with Adverse events as a measure of Safety and Tolerability | 12 months | ||
Secondary | Number of re-treatments and re-treatment patterns | Number of re-treatments and re-treatment patterns (eg: duration of treatment-free intervals; duration of active treatment phase) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Active, not recruiting |
NCT04120311 -
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Not yet recruiting |
NCT04601688 -
Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Completed |
NCT01968239 -
Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
|
Phase 2 | |
Completed |
NCT00612261 -
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
|
N/A | |
Not yet recruiting |
NCT03637283 -
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
|
N/A | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Completed |
NCT01247220 -
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
|
Phase 2 | |
Terminated |
NCT00642226 -
Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Terminated |
NCT05127525 -
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
|
Phase 3 | |
Completed |
NCT01599650 -
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
|
Phase 3 | |
Active, not recruiting |
NCT04120636 -
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Recruiting |
NCT01975103 -
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A | |
Completed |
NCT04740905 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT02527733 -
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
|
Phase 4 | |
Completed |
NCT01396057 -
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Terminated |
NCT03802630 -
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
|
Phase 3 | |
Completed |
NCT02478515 -
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
|
Phase 4 | |
Terminated |
NCT01795209 -
Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
|
Phase 4 |